{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:11:50Z","timestamp":1777579910538,"version":"3.51.4"},"reference-count":31,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kite"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Hematopoietic cell transplantation (HCT) is an established therapy for hematologic malignancies and serious non-malignant blood disorders. Despite its curative potential, HCT is associated with substantial toxicity and health resource utilization. Effective delivery of HCT requires complex hospital-based care, which limits the number of HCT centres in Canada. In Canada, the quantity, indications, temporal trends, and outcomes of patients receiving HCT are not known. Methods: A retrospective cohort study of first transplants reported to the Cell Therapy Transplant Canada (CTTC) registry between 2000 and 2019. We determined overall survival (OS) and non-relapse mortality (NRM), categorizing the cohort into early (2000\u20132009) and later (2010\u20132019) eras to investigate temporal changes. Results: Of 18,046 transplants, 7571 were allogeneic and 10,475 were autologous. Comparing the two eras, allogeneic transplants increased in number by 22.3%, with greater use of matched unrelated donors in the later era. Autologous transplants increased by 10.9%. Temporal improvements in NRM were observed in children and adults. OS improved in pediatric patients and in adults receiving autologous HCT. In adults receiving allogeneic HCT, OS was stable despite the substantially older age of patients in the later era. Interpretation: HCT is an increasingly frequent procedure in Canada which has expanded to serve older adults. Noted improvements in NRM and OS reflect progress in patient and donor selection, preparation for transplant, and post-transplant supportive care. In allogeneic HCT, unrelated donors have become the most frequent donor source, highlighting the importance of the continued growth of volunteer donor registries. These results serve as a baseline measure for quality improvement and health services planning in Canada.<\/jats:p>","DOI":"10.3390\/curroncol30110723","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T10:10:06Z","timestamp":1700215806000},"page":"9953-9967","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hematopoietic Cell Transplantation Trends and Outcomes in Canada: A Registry-Based Cohort Study"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0960-2687","authenticated-orcid":false,"given":"Matthew D.","family":"Seftel","sequence":"first","affiliation":[{"name":"Canadian Blood Services, Vancouver, BC V6H 2N9, Canada"},{"name":"Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7595-0113","authenticated-orcid":false,"given":"Ivan","family":"Pasic","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada"},{"name":"Faculty of Medicine, University of Toronto, Toronto, ON M5G 2M9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaganvir","family":"Parmar","sequence":"additional","affiliation":[{"name":"Canadian Blood Services, Vancouver, BC V6H 2N9, Canada"},{"name":"Faculty of Medicine, University of Toronto, Toronto, ON M5G 2M9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1673-9451","authenticated-orcid":false,"given":"Oliver","family":"Bucher","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, CancerCare Manitoba, Winnipeg, MB R3A 1M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Allan","sequence":"additional","affiliation":[{"name":"Canadian Blood Services, Vancouver, BC V6H 2N9, Canada"},{"name":"Department of Medicine and Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sita","family":"Bhella","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada"},{"name":"Faculty of Medicine, University of Toronto, Toronto, ON M5G 2M9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9398-2677","authenticated-orcid":false,"given":"Kevin Anthony","family":"Hay","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada"},{"name":"Division of Hematology, Department of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada"},{"name":"Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluwaseun","family":"Ikuomola","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, CancerCare Manitoba, Winnipeg, MB R3A 1M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Musto","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, CancerCare Manitoba, Winnipeg, MB R3A 1M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca","family":"Prica","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada"},{"name":"Faculty of Medicine, University of Toronto, Toronto, ON M5G 2M9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Richardson","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, CancerCare Manitoba, Winnipeg, MB R3A 1M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony H.","family":"Truong","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, Department of Pediatrics, University of Calgary, Calgary, AB T3B 6A8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristjan","family":"Paulson","sequence":"additional","affiliation":[{"name":"Cell Therapy and Transplant Canada, Winnipeg, MB R3E 0V9, Canada"},{"name":"Department of Medical Oncology and Haematology, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for Haematopoietic Cell Transplantation for Haematological Diseases, Solid Tumours and Immune Disorders: Current Practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.12968\/hmed.2019.80.1.33","article-title":"Haematopoietic Stem Cell Transplants: Principles and Indications","volume":"80","author":"Balassa","year":"2019","journal-title":"Br. J. Hosp. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/978-1-61779-842-9_30","article-title":"Donor Registries and Search Strategies","volume":"882","author":"Hurley","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bbmt.2011.12.519","article-title":"Recommended Screening and Preventive Practices for Long-Term Survivors after Hematopoietic Cell Transplantation","volume":"18","author":"Majhail","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.6004\/jnccn.2020.0021","article-title":"Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Saad","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bmt.1705445","article-title":"Haploidentical Hematopoietic Stem Cell Transplantation without in Vitro T-Cell Depletion for the Treatment of Hematological Malignancies","volume":"38","author":"Huang","year":"2006","journal-title":"Bone Marrow Transplant."},{"key":"ref_10","unstructured":"Bolon, Y., Atshan, R., Allbee-Johnson, M., Estrada-Merly, N., and Lee, S. (2022). Current Use and Outcome of Hematopoietic Stem Cell Transplantation: CIBMTR Summary Slides, CIBMTR."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","article-title":"Hematopoietic Cell Transplantation and Cellular Therapy Survey of the EBMT: Monitoring of Activities and Trends over 30 Years","volume":"56","author":"Passweg","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","article-title":"How Much Has Allogeneic Stem Cell Transplant-Related Mortality Improved since the 1980s? A Retrospective Analysis from the EBMT","volume":"4","author":"Penack","year":"2020","journal-title":"Blood Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.2012.46.6193","article-title":"Significant Improvement in Survival after Allogeneic Hematopoietic Cell Transplantation during a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors","volume":"31","author":"Hahn","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.bbmt.2015.10.019","article-title":"Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis","volume":"22","author":"Rashidi","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.bbmt.2019.05.037","article-title":"Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"Boumendil","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3324\/haematol.2014.103655","article-title":"Geriatric Assessment to Predict Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients","volume":"99","author":"Muffly","year":"2014","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1182\/bloodadvances.2020001719","article-title":"Geriatric Assessment in Older AlloHCT Recipients: Association of Functional and Cognitive Impairment with Outcomes","volume":"4","author":"Olin","year":"2020","journal-title":"Blood Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/j.bbmt.2020.06.007","article-title":"Recent Advances in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia","volume":"26","author":"Bittencourt","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.bbmt.2009.07.007","article-title":"Impact of Declining Fertility Rates in Canada on Donor Options in Blood and Marrow Transplantation","volume":"15","author":"Allan","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbmt.2015.09.012","article-title":"On Modeling Human Leukocyte Antigen\u2013Identical Sibling Match Probability for Allogeneic Hematopoietic Cell Transplantation: Estimating the Need for an Unrelated Donor Source","volume":"22","author":"Besse","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with Anti-Thymocyte Globulin versus No Anti-Thymocyte Globulin in Patients with Haematological Malignancies Undergoing Haemopoietic Cell Transplantation from Unrelated Donors: A Randomised, Controlled, Open-Label, Phase 3, Multicentre Trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-Resolution Donor-Recipient HLA Matching Contributes to the Success of Unrelated Donor Marrow Transplantation","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.tmrv.2018.11.003","article-title":"Peripheral Blood or Bone Marrow Stem Cells? Practical Considerations in Hematopoietic Stem Cell Transplantation","volume":"33","author":"Amouzegar","year":"2019","journal-title":"Transfus. Med. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3324\/haematol.2016.156356","article-title":"Improved Survival after Acute Graft-versus-Host Disease Diagnosis in the Modern Era","volume":"102","author":"Khoury","year":"2017","journal-title":"Haematologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bbmt.2015.01.001","article-title":"A Refined Risk Score for Acute Graft-versus-Host Disease That Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality","volume":"21","author":"MacMillan","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Kong, S.G., Jeong, S., Lee, S., Jeong, J.-Y., Kim, D.J., and Lee, H.S. (2021). Early Transplantation-Related Mortality after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Leukemia. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-07897-3"},{"key":"ref_28","first-page":"784377","article-title":"Current Prophylaxis and Treatment Approaches for Acute Graft-Versus-Host Disease in Haematopoietic Stem Cell Transplantation for Children with Acute Lymphoblastic Leukaemia","volume":"9","author":"Qayed","year":"2021","journal-title":"Front. Pediatr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.bbmt.2017.11.004","article-title":"Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis","volume":"24","author":"Qayed","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies","volume":"370","author":"Altman","year":"2007","journal-title":"Lancet"},{"key":"ref_31","unstructured":"(2023, November 07). C.W. Bill Young Transplantation Program, Available online: https:\/\/bloodstemcell.hrsa.gov\/about\/legislation."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/11\/723\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:24:46Z","timestamp":1760131486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/11\/723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["curroncol30110723"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30110723","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,17]]}}}